RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $203

Benzinga Newsdesk www.benzinga.com Positive 92.1%

Neg 0% Neu 0% Pos 92.1%

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $182 to $203.